Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers. (31st December 2022)

• Record Type: Journal Article
• Authors: Liu, Youqiang; Zhang, Hongxin; Cui, Haijing; Zhang, Futong; Zhao, Liyan; Liu, Yibing; Meng, Qingju
• Is Part Of: Drug delivery. Volume 29:Number 1(2022)
• Page Start: 342
• Page End: 350
• Publication Date: 2022-12-31
• Subjects: Colorectal cancer -- irinotecan prodrug -- lipid nanoparticles -- reactive oxygen species sensitive; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2022.2027573
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Purpose: Colorectal cancer (CRC) is the third most frequently diagnosed cancer and this study aimed to develop a conatumumab decorated, irinotecan prodrug and quercetin co-loaded delivery system for combined and targeted colorectal cancer treatment. Methods: A conatumumab (C) decorated, irinotecan prodrug (I-p) and quercetin (Q) co-encapsulated NLC (C I-p/Q NLC) was developed. In vitro and in vivo antitumor efficiency of NLC was evaluated on CRC cells and mice xenograft. Results: The results showed that the HT-29 cells uptake of C I-p/Q NLC was over 70%. Reactive oxygen species (ROS) sensitive irinotecan prodrug formulation showed improved drug release ability in hypoxic conditions. C I-p/Q NLC showed significantly higher cytotoxicity than non-decorated NLC, single drug-loaded NLC and free drugs. In vivo studies in a CRC-bearing model corroborated the capability of nanoparticles for the inhibition of cancer, leading to a reduction of tumor growth without systemic toxicity. Conclusion: The conatumumab decorated, ROS sensitive prodrug contained combination nano-system is a promising platform for CRC therapy.